Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930136

Cover Image

PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930136

Sciatica Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

PUBLISHED:
PAGES: 110 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4850
Unprintable PDF & Excel (Multi User License)
USD 5850
PDF, Excel & PPT (Enterprise License)
USD 6850

Add to Cart

Growth Factors of sciatica treatment Market

The global sciatica treatment market was valued at USD 5.92 billion in 2025 and is projected to grow from USD 6.52 billion in 2026 to USD 14.42 billion by 2034, registering a strong CAGR of 10.44% during the forecast period. North America dominated the market with a 46.1% share in 2025, supported by high awareness of chronic lower back pain, increased prescription volumes, and the presence of leading pharmaceutical companies.

Sciatica, also known as lumbar radicular pain, is characterized by pain radiating from the lower back to the legs due to compression or irritation of the sciatic nerve. The rising incidence of herniated discs, spinal stenosis, and lumbar radiculopathy is driving demand for effective pharmacological and interventional treatment options worldwide.

Market Drivers

A key driver of market growth is the increasing prevalence of sciatica globally, with annual incidence rates ranging from 1.0% to 5.0% and lifetime prevalence between 13% and 40%. The growing use of over-the-counter and prescription drugs, including NSAIDs, corticosteroids, antidepressants, and opioids, has significantly contributed to treatment adoption.

Rising awareness of advanced treatment modalities such as epidural steroid injections and analgesic therapies, along with increased clinical trial activity by market players, is further accelerating market expansion. Additionally, the lack of long-term FDA-approved therapies has encouraged companies to invest in innovative drug development programs.

COVID-19 Impact

The COVID-19 pandemic negatively affected the sciatica treatment market in 2020 due to reduced hospital visits and disruptions in pharmaceutical manufacturing and supply chains. Prescription volumes declined as healthcare systems prioritized COVID-19 care.

However, post-pandemic recovery led to a rebound in patient visits for chronic conditions. By 2021, the relaxation of restrictions resulted in increased demand for sciatica treatments, with pharmaceutical companies witnessing growth in prescription drug sales across hospitals and retail pharmacies.

Market Trends

One of the major trends shaping the market is the rise in awareness programs initiated by healthcare authorities and research institutions. Increased public knowledge about sciatica symptoms, risk factors, and treatment options has improved early diagnosis and treatment uptake.

National and regional initiatives focusing on chronic lower back pain management and the promotion of non-opioid pain therapies are influencing prescribing patterns. The growing availability of minimally invasive procedures and non-opioid medications across healthcare settings is further strengthening market growth.

Restraining Factors

Despite strong growth prospects, the market faces restraints due to side effects and complications associated with long-term sciatica treatments. Chronic use of corticosteroids, opioids, and invasive procedures can lead to significant morbidity, limiting their adoption.

Additionally, sciatica treatment imposes a substantial economic burden due to high direct and indirect healthcare costs. Limited long-term efficacy of existing therapies and concerns regarding complications such as infections and systemic side effects may restrict market growth.

Segmentation Analysis

By Type:

The chronic sciatica segment dominated the market with a 71.47% share in 2026, driven by the high prevalence of long-lasting pain and increased use of epidural injections and opioid therapies. The acute segment is expected to grow steadily due to rising awareness and early treatment adoption.

By Drug Class:

The NSAIDs segment accounted for 44.17% of the market in 2026, supported by widespread availability, affordability, and frequent prescriptions. Corticosteroids are anticipated to witness the fastest growth due to rising demand for epidural steroid injections.

By Distribution Channel:

The retail and online pharmacies segment dominated with an 80.52% share in 2026, driven by high out-of-pocket spending and easy access to pain management medications. Hospital pharmacies are expected to grow steadily due to increasing patient admissions.

Regional Insights

  • North America: Valued at USD 2.73 billion in 2025, driven by high prescription rates and awareness. The U.S. market is projected to reach USD 2.93 billion by 2026.
  • Europe: Moderate growth supported by high disease prevalence and structured pain management guidelines.
  • Asia Pacific: Strong growth potential due to rising lower back pain incidence and government initiatives. By 2026, Japan is projected to reach USD 0.28 billion, China USD 0.24 billion, and India USD 0.17 billion.
  • Latin America & Middle East & Africa: Expected to grow steadily due to expanding access to pain management therapies.

Competitive Landscape

Key players include Pfizer Inc., Abbott, Bayer AG, Johnson & Johnson, Novartis AG, GSK plc., and Sorrento Therapeutics. These companies focus on portfolio expansion, clinical trials, and strategic collaborations to strengthen their market presence.

Conclusion

The global sciatica treatment market is set to witness robust growth from 2025 to 2034, driven by rising disease prevalence, increasing awareness, and growing demand for effective pain management solutions. While concerns regarding side effects and long-term efficacy remain, ongoing clinical research, new drug development, and supportive healthcare initiatives are expected to sustain market momentum. By 2034, the market is projected to reach USD 14.42 billion, reflecting the expanding need for advanced and safer sciatica treatment options worldwide.

Segmentation By Type

  • Acute
  • Chronic

By Drug Class

  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Antidepressants
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By Region

  • North America (By Type, Drug Class, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa
Product Code: FBI108950

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Sciatica, By Key Countries, 2025
  • 4.2. Recent Product Launches, By Key Players
  • 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.4. Impact of COVID-19 on the Global Market

5. Global Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Acute
    • 5.1.2. Chronic
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 5.2.2. Corticosteroids
    • 5.2.3. Antidepressants
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail & Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East and Africa

6. North America Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Acute
    • 6.1.2. Chronic
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 6.2.2. Corticosteroids
    • 6.2.3. Antidepressants
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail & Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Acute
    • 7.1.2. Chronic
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 7.2.2. Corticosteroids
    • 7.2.3. Antidepressants
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail & Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Acute
    • 8.1.2. Chronic
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.2.2. Corticosteroids
    • 8.2.3. Antidepressants
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail & Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Acute
    • 9.1.2. Chronic
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 9.2.2. Corticosteroids
    • 9.2.3. Antidepressants
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail & Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Acute
    • 10.1.2. Chronic
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 10.2.2. Corticosteroids
    • 10.2.3. Antidepressants
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail & Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of MEA

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Abbott
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Bayer AG
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Endo International plc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Johnson & Johnson Services, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. GSK plc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Novartis AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Bristol Myers Squibb
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. Amneal Pharmaceuticals LLC.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)
    • 11.2.10. Sorrento Therapeutics
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. financials (Based on Availability)
Product Code: FBI108950

List of Tables

  • Table 1: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by By Drug Class, 2021-2034
  • Table 3: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Sciatica Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 11: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 15: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 19: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Sciatica Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Sciatica Treatment Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Sciatica Treatment Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 4: Global Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Sciatica Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 8: North America Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Sciatica Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Sciatica Treatment Market Value Share (%), By Country, 2025
  • Figure 14: Europe Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 16: Europe Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 17: Europe Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 18: Europe Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 25: Asia Pacific Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 26: Asia Pacific Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Latin America Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 34: Latin America Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 41: Middle East & Africa Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 42: Middle East & Africa Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Sciatica Treatment Market Share (%), By Company, 2025
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!